Showing 4181-4190 of 5646 results for "".
- Samsara Vision Announces First US Surgeries of the SING IMT for AMD as Part of the CONCERTO Studyhttps://modernod.com/news/samsara-vision-announces-first-us-surgeries-of-the-sing-imt-for-aamd-as-part-of-the-concerto-study/2480955/Samsara Vision announced the completion of the first US surgeries of its SING IMT (Smaller-Incision New-Generation Implantable Miniature Telescope), as part of the CONCERTO clinical study, a US-based FDA study to evaluate improvements in visual acuity and safety of the device
- RetinalGeniX Technologies Acquires DNA/GPS Inc.https://modernod.com/news/retinalgenix-technologies-acquires-dnagps-inc/2480949/RetinalGeniX Technologies announced the acquisition of DNA/GPS. Terms of the deal were not disclosed. The acquisition gives RetinalGeniX the rights to the platform technology designed by Larry Perich, MD, which is designed to al
- OliX Pharmaceuticals Announces IND Submission to FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trialhttps://modernod.com/news/olix-pharmaceuticals-announces-ind-submission-to-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial/2480945/OiX Pharmaceuticals announced the submission of an investigational new drug (IND) application to the FDA to evaluate the safety and tolerability of OLX10212 for the treatment of advanced age-related macular degeneration (AMD). The objective of this phase 1 study is to determine the safety an
- Ocuphire Granted New US Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabeticshttps://modernod.com/news/ocuphire-granted-new-us-patent-for-late-stage-oral-drug-candidate-apx3330-for-use-in-diabetics/2480941/Ocuphire Pharma announced that the United States Patent and Trademark Office (USPTO) has issued a new patent extending expiry and broadening coverage of the company’s late-stage oral product candidate, APX3330, for diabetic eye disease. In addition, a new publication supporting the nov
- Oculis Announces First Patient Enrolled in Phase 3 OPTIMIZE Trial of OCS-01 in the Treatment of Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-announces-first-patient-enrolled-in-phase-3-optimize-trial-of-ocs-01-in-the-treatment-of-inflammation-and-pain-following-cataract-surgery/2480939/Oculis SA announced that the first patient has been enrolled in its phase 3 OPTIMIZE trial evaluating the efficacy and safety of once-daily OCS-01 for the treatment of inflammation and pain following cataract surgery. OCS-01 is a novel, high concentration, preservative-free, topical formulat
- Oyster Point Pharma Announces Restructuring Plan to Reduce Costshttps://modernod.com/news/oyster-point-pharma-announces-operating-expense-streamlining-plan/2480938/Oyster Point Pharma announced it will implement an operating expense streamlining plan that will include a reduction of employee and non-employee expenses across the organization. The company plans to continue to drive the launch of Tyrvaya with approximately 150-200 fie
- Formosa Pharmaceuticals and AimMax Therapeutics Announce Topline Results from CPN-301 for the Treatment of Inflammation and Pain After Cataract Surgeryhttps://modernod.com/news/formosa-pharmaceuticals-and-aimmax-therapeutics-announce-successful-topline-results-from-cpn-301-for-the-treatment-of-inflammation-and-pain-after-cataract-surgery/2480937/Formosa Pharmaceuticals and AimMax Therapeutics reported successful topline results from CPN-301, the first of two pivotal phase 3 clinical studies of APP13007, a novel ophthalmic nanosuspension formulation of a corticosteroid, clobetasol propionate(0.05%), for the treatment of inflamma
- NPR Report: He and His Wife Both Got Cataract Surgery. His Bill Was 20 times Higher Than Hershttps://modernod.com/news/npr-report-he-and-his-wife-both-got-cataract-surgery-his-bill-was-20-times-higher-than-hers/2480934/A NPR report shares an example of the factors involved in how insurance companies determine reimbursement for cataract surgery. The articl
- Foundation Fighting Blindness Announces Leadership Changeshttps://modernod.com/news/foundation-fighting-blindness-announces-leadership-changes/2480924/The Foundation Fighting Blindness announced the promotions of Jason Menzo to chief executive officer of the Foundation, and Russell Kelley, PhD, MBA, to managing director of the Retinal Degeneration (RD) Fund, the venture arm of the Foundation, effective Ju
- Opus Genetics Appoints Ben Yerxa, PhD, as Permanent Chief Executive Officerhttps://modernod.com/news/opus-genetics-appoints-ben-yerxa-phd-as-permanent-chief-executive-officer/2480923/Opus Genetics announced the appointment of Ben Yerxa, PhD, as Chief Executive Officer. Dr. Yerxa previously served as acting CEO of Opus, in addition to former roles as CEO of the Foundation Fighting Blindness and the Retinal Degeneration (RD) Fund, the venture arm of th